Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IDAMYCIN PFS vs CERUBIDINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.
Treatment of acute myeloid leukemia (AML) in adults,Treatment of acute lymphocytic leukemia (ALL) (off-label)
Acute myeloid leukemia,Acute lymphoblastic leukemia,Chronic myeloid leukemia in blast crisis,Kaposi's sarcoma (off-label)
12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).
45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.
Terminal elimination half-life of idarubicin is 20-30 hours; idarubicinol (active metabolite) has a terminal half-life of 45-60 hours, extending myelosuppression duration.
Triphasic elimination: initial half-life 30 min (distribution), intermediate 3-5 hours (metabolism), terminal half-life 20-30 hours (slow elimination from tissues). Clinically relevant for scheduling and myelosuppression monitoring.
Hepatic metabolism primarily via aldo-keto reductases to idarubicinol (active metabolite); further metabolism via glucuronidation.
Primarily hepatic metabolism via aldo-keto reductases to daunorubicinol (active metabolite), and further via CYP2D6 and carbonyl reductases.
Renal (approximately 5-12% as unchanged drug and metabolites), biliary/fecal (significant, with 40-50% recovered in feces over 7 days).
Primarily hepatic metabolism with biliary excretion (about 40% as unchanged drug and metabolites in bile). Renal excretion accounts for approximately 8-15% of the dose as unchanged drug and metabolites. Fecal elimination is less than 20%.
Idarubicin: 94-97% bound to plasma proteins (primarily albumin); idarubicinol: 90-95% bound.
Approximately 50-70% bound to plasma proteins, primarily albumin.
Vd: 40-90 L/kg (extensive tissue distribution, indicating high affinity for intracellular sites such as DNA).
Volume of distribution is high, ranging from 15-30 L/kg, indicating extensive tissue binding and distribution, particularly into erythrocytes and tissues.
Oral bioavailability: approximately 30% (limited clinical use; idarubicin is typically administered IV).
Oral bioavailability is less than 5% due to extensive first-pass metabolism; therefore, not administered orally. IV administration results in 100% bioavailability.
GFR 20-50 m L/min: Administer 75% of dose; GFR <20 m L/min: Administer 50% of dose. Not dialyzable; no supplemental dose needed post-dialysis.
Cr Cl 10–50 m L/min: reduce dose by 25%; Cr Cl <10 m L/min: reduce dose by 50%. Hemodialysis: administer after dialysis; dose reduction by 50%.
Child-Pugh Class B: Reduce dose by 25%; Child-Pugh Class C: Reduce dose by 50%. Severe hepatic dysfunction (bilirubin >3 mg/d L): Contraindicated unless benefit outweighs risk.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Children: 12 mg/m² intravenously daily for 3 days (induction) or 12 mg/m² daily for 2 days (consolidation). For infants <0.5 m²: 0.75 mg/kg intravenously daily for 3 days.
25–45 mg/m² IV on days 1–3 every 21 days; neonates: <10 kg: 1 mg/kg IV daily for 3–5 days.
No specific dose adjustment, but monitor for increased myelosuppression and cardiotoxicity. Consider dose reduction based on renal function and performance status.
Initiate at lower end of dose range (30 mg/m²/day for 3 days) due to increased myelotoxicity; monitor renal function.
Severe myelosuppression when used at therapeutic doses; cardiac toxicity including potentially fatal congestive heart failure, acute left ventricular failure, and arrhythmias; secondary malignancies including acute myeloid leukemia and myelodysplastic syndrome; extravasation leading to severe tissue necrosis; reduce dose in patients with hepatic impairment.
Severe myelosuppression; cumulative dose-related cardiotoxicity; extravasation with tissue necrosis; secondary leukemias.
Monitor cardiac function before and during therapy; cumulative dose increases risk of cardiotoxicity,Severe myelosuppression with risk of infection and bleeding,Extravasation risk: administer via secure IV line,Secondary malignancies reported,Hepatic and renal impairment may require dose adjustment,Tumor lysis syndrome,May impair fertility
Bone marrow suppression; cardiac toxicity (cumulative doses >550 mg/m²); hepatic and renal impairment; tumor lysis syndrome; immunosuppression.
Hypersensitivity to idarubicin or other anthracyclines,Severe hepatic impairment (Child-Pugh class C),Severe renal impairment (creatinine clearance < 30 m L/min),Pre-existing severe myelosuppression not due to leukemia,Severe cardiac dysfunction (e.g., recent myocardial infarction, cardiomyopathy)
Severe myelosuppression; previous anthracycline therapy at maximum cumulative dose; severe hepatic impairment; severe cardiac disease; pregnancy.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition affecting drug metabolism. No other significant food interactions.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing toxicity. No other specific food restrictions reported.
Idarubicin is embryotoxic and teratogenic in animal studies. Human data are limited, but it is classified as FDA Pregnancy Category D. There is evidence of fetal risk in the first trimester, including malformations and spontaneous abortion. In the second and third trimesters, there is risk of fetal growth restriction, preterm labor, and neonatal myelosuppression. Use only if potential benefit justifies risk.
Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal growth restriction, prematurity, and neonatal myelosuppression.
It is unknown if idarubicin is excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and carcinogenesis, breastfeeding is contraindicated during treatment and for at least 1 month after the last dose. M/P ratio is not established.
Contraindicated during breastfeeding. Daunorubicin is excreted into breast milk; M/P ratio unknown due to limited data. Potential for severe adverse effects in nursing infant including immunosuppression, cardiotoxicity, and carcinogenesis.
No specific dose adjustments have been established for pregnancy. Physiological changes in pregnancy (increased plasma volume, altered hepatic metabolism) may affect pharmacokinetics but no formal studies exist. Use standard dosing based on body surface area with caution and monitor for toxicity.
No established dosing adjustments for pregnancy. Standard dosing based on body surface area, but use only if clearly needed due to teratogenicity. Increased volume of distribution may alter pharmacokinetics, but formal dose modifications not defined.
Administer IV only; extravasation causes severe tissue necrosis. Premedicate with antiemetics. Monitor for cardiotoxicity with cumulative doses >550 mg/m2 (or 450 mg/m2 with prior chest irradiation). Urine may turn reddish for 1-2 days. Leukocyte nadir occurs 10-14 days after administration.
Cerubidine (daunorubicin) is an anthracycline antineoplastic antibiotic; premedicate with antiemetics; monitor for cardiotoxicity (cumulative dose limit 550 mg/m², or 450 mg/m² with prior chest radiation); administer via IV over 15-30 minutes to avoid extravasation (vesicant); observe for rapid lysis syndrome in high-tumor-burden patients; adjust dose for hepatic impairment (bilirubin >1.2 mg/d L).
This drug can cause severe nausea and vomiting; take antiemetics as prescribed.,Your urine may appear red or orange for 1-2 days after treatment; this is normal.,Report any pain, redness, or swelling at the injection site immediately.,Avoid receiving live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 6 months after therapy.
This drug may cause irreversible heart damage at high cumulative doses; report chest pain, shortness of breath, or swelling of ankles/feet.,You will need regular blood tests to monitor blood cell counts and heart function.,Notify your healthcare provider immediately if you experience pain, redness, or swelling at the injection site.,This medication can cause severe nausea and vomiting; antiemetic therapy will be given.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception; do not breastfeed while on this medication.,Your urine may appear reddish-orange for 1-2 days after treatment; this is harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IDAMYCIN PFS vs CERUBIDINE, answered by our medical review team.
IDAMYCIN PFS is a Anthracycline Antineoplastic that works by Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.. CERUBIDINE is a Anthracycline antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IDAMYCIN PFS and CERUBIDINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IDAMYCIN PFS is: 12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).. The standard adult dose of CERUBIDINE is: 45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IDAMYCIN PFS and CERUBIDINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IDAMYCIN PFS is classified as Category C. Idarubicin is embryotoxic and teratogenic in animal studies. Human data are limited, but it is classified as FDA Pregnancy Category D. There is evidence of fetal risk in the first . CERUBIDINE is classified as Category C. Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.